ClinicalTrials.gg

Program

camoteskimab

Also written as “MEDI2338”, “Camoteskimab” and “AEVI-007”.

Its studies are mostly in Dermatitis, Atopic · Multiple Myeloma · Still's Disease, Adult-Onset · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Furthest: phase 2, since Apr 9, 20245 company-led studies, 1 open or runningNext primary completion: Oct 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Apollo Therapeutics31 open or runningphase 2since Apr 9, 2024Feb 9, 2021Oct 31, 2027phase 2 · NCT07599813
AstraZeneca10 open or runningphase 1since Mar 23, 2011Mar 23, 2011none ahead
Avalo Therapeutics10 open or runningphase 1since Dec 1, 2020Dec 1, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2011First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to AstraZenecaAstraZeneca · NCT01322594 · 31 enrolled · South Africa, United Kingdom
  2. Dec 1, 2020Avalo Therapeutics's first study: phase 1 study in Multiple MyelomaNew to Avalo TherapeuticsAvalo Therapeutics · NCT04671251 · 13 enrolled · United States
  3. Feb 9, 2021Apollo Therapeutics's first study: phase 1 study in Still's Disease, Adult-OnsetNew to Apollo TherapeuticsApollo Therapeutics · NCT04752371 · 5 enrolled · United States, Belgium, Poland and more
  4. Apr 9, 2024Phase 2 study in Dermatitis, AtopicApollo Therapeutics · NCT06436183 · 62 enrolled · United States, Canada
  5. May 15, 2026Phase 2 study in Dermatitis, AtopicApollo Therapeutics · NCT07599813 · 280 planned · United States, Bulgaria, Canada and more

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Dermatitis, AtopicApollo Therapeutics · NCT07599813

TargetBeta

IL18 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin-18 (IL-18), ”NCIt, by rule
“Interleukin-18 cross-linking agent”ChEMBL 37, by rule

Other programs on IL18

ProgramCompanyFurthest phaseStudies
aletekitugruleGlaxoSmithKlinephase 29
arumakimigNovartisphase 27
GHZ339Novartisphase 21
BLN-481rulebeeline-medicines-corporationphase 11
GSK4528287GlaxoSmithKlinephase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07599813Dermatitis, Atopic · United States, Bulgaria, Canada and more2RecruitingApollo TherapeuticsOct 31, 2027280
NCT06436183Dermatitis, Atopic · United States, Canada2CompletedApollo TherapeuticsMar 26, 202562
NCT04752371Still's Disease, Adult-Onset · United States, Belgium, Poland and more1TerminatedApollo TherapeuticsMay 24, 20225
NCT04671251Multiple Myeloma · United States1CompletedAvalo TherapeuticsMar 30, 202213
NCT01322594Pulmonary Disease, Chronic Obstructive · South Africa, United Kingdom1CompletedAstraZenecaNov 201131

How it is read

Names in the registry

  • “MEDI2338”, 5 entries
  • “Camoteskimab”, 2 entries
  • “AEVI-007”, 1 entry
  • “Camoteskimab (CERC-007, AVTX-007, AEVI-007)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.